



## **CooperVision Leads Global Dialogue on Myopia Control, Bridging Optometry and Ophthalmology Professions**

Commitment.to.Advancing.Ocular.Health.Highlighted.at.WCPOS.V.and.WOC.Events?Emphasizing.Collaboration.and.Innovation

**ROCHESTER, New York, July 25, 2024**—CooperVision's leadership in advancing myopia control and establishing it as the standard of care in ocular health was prominently featured at the recent [World Congress of Paediatric Ophthalmology and Strabismus \(WCPOS V\)](#) in Kuala Lumpur, Malaysia. Continuing this momentum, CooperVision will also be showcased at the upcoming [World Ophthalmology Congress \(WOC\)](#) in Vancouver, Canada. These engagements underscore the company's commitment to fostering collaboration between ophthalmology and optometry professionals worldwide.

“Ophthalmology and the optometry communities are equally pivotal in driving adoption and standards of care, uncovering critical insights, and shaping the future of myopia control and management—endeavors we are honored to support and enhance,” said Elizabeth Lumb, BSc (Hons) MCOptom, FIACLE, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision. “Leveraging both communities is crucial for developing a unified approach to myopia management, which can lead to reaching more patients with aligned treatment approaches.”

During WCPOS V, CooperVision hosted the 2024 APAC Luminary Event, successfully bridging ophthalmology and optometry through an active roundtable discussion aimed at creating an industry white paper. Eye care professionals (ECPs) from both professions contributed insights to the forthcoming publication, "Joint Consensus on Standardizing Clinical Use of Contact Lenses for Myopia Management Across Ophthalmology and Optometry."

In addition, CooperVision engaged both professions by presenting the results of its MiSight® 1 day seven-year clinical study. Professor Nicola Logan, Principal Investigator of the MiSight® 1 day clinical trial at Aston University, shared these insights along with findings from a separate investigator-initiated study at the company's sponsored lunch symposium. Additionally, five scientific posters provided further evidence-based perspectives and practical strategies for managing myopia progression in children.

Later this summer, CooperVision will sponsor the International Medical Contact Lens Council (IMCLC) Symposium to be held at WOC on August 16. The event, “Innovation in Contact Lens Use,” will convene global ophthalmology experts to discuss CooperVision’s advancements in myopia control. It will also underscore IMCLC’s dedication to worldwide education and information dissemination on contact lens-related topics for providers.

“Our involvement in these conferences demonstrates CooperVision's unwavering commitment to the ophthalmology community and highlights our dedication to advancing the understanding and management of childhood myopia through evidence-based strategies,” said Lumb. “By spotlighting groundbreaking advancements in myopia control, CooperVision is facilitating meaningful dialogue and driving collective action within both fields, addressing the urgent need for a coordinated strategy to tackle the growing challenge of myopia.”

For more information on these two events, visit [wcposv2024.org](http://wcposv2024.org) and [icowoc.org](http://icowoc.org).

###

### **About CooperVision**

CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit [www.coopervision.com](http://www.coopervision.com).

### **About CooperCompanies**

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a

workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit [www.coopercos.com](http://www.coopercos.com).

**Media Contact**

Laura DiCaprio

McDougall Communications for CooperVision

[laura@mcdougallpr.com](mailto:laura@mcdougallpr.com) or 585-434-2153